Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : SANGUINE CORP. (SGNC) -- Ignore unavailable to you. Want to Upgrade?

To: Profiteer who wrote (4223)	9/23/1998 10:10:00 PM
From: Prospector	Respond to of 5402

This is a repost that was a very important question that the Dr was asked last night.... about why Japan did not pursue their FDA approval. I know allot of people don't understand why... I asked Dr. Drees if there was any way that Green Cross (When Dr. Drees was president of Alpha , the American subsidary of Green Cross, Alpha received FDA approval for the first generation version of this product.) could sell this product or the previous product that they had previously used on approximately 13,000 people. Dr. Drees replied that they could not. The reason why is that when they falsified the date (not data) that they had given one patient the drug, eventually they got caught, and were forced to withdraw their application for product approval in Japan. Green Cross also dropped their FDA approval in the United States. Does Green Cross have the patent on the first generation drug? No, the reason why is that the professors from Harvard, Pennsylvania University, and the University of Cincinnati were the ones that started the research. When these professors applied to Washington to get funding they were denied 2 years in a row. Japan heard about the research and invested in it. However, it was not their (Green Cross) invention and therefore they never got a patent. (RG) Sanguine has patents pending and is currently conducting research and development leading to FDA clinical trials of PHER-02. In 1994, Sanguine and Battelle Memorial Research Institute devoloped three additional unique proprietary synthetic blood compounds using newly developed surfactants. Battelle has completed extensive patent searches to insure the proprietary nature of these new compounds and Sanguine plans to file the necessary additional patent applications. The next phase will be gross animal testing (which is going on now) leading to an investigational new drug appliction to the FDA. Sanguine and Battelle are very encouraged by these compounds as they eliminate many of the drawbacks of the first generation formula, developed by Alpha Therapeutics, which was approved by the FDA. (courtesy of Prospector)